Affiliations 

  • 1 Experimental Therapeutics Center, Institute of Pharmaceuticals and Nutraceuticals Malaysia, Blok 5-A, Halaman Bukit Gambir, Penang 11700, Malaysia. waikwan@ipharm.gov.my
  • 2 Biomolecular Research Group, Biochemistry Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia. gbh-85@hotmail.com
  • 3 Biomolecular Research Group, Biochemistry Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia. habsah@um.edu.my
  • 4 Experimental Therapeutics Center, Institute of Pharmaceuticals and Nutraceuticals Malaysia, Blok 5-A, Halaman Bukit Gambir, Penang 11700, Malaysia. alex@usm.my
  • 5 Experimental Therapeutics Center, Institute of Pharmaceuticals and Nutraceuticals Malaysia, Blok 5-A, Halaman Bukit Gambir, Penang 11700, Malaysia. sifzizul@umt.edu.my
Molecules, 2015;20(12):22301-14.
PMID: 26703529 DOI: 10.3390/molecules201219847

Abstract

Numerous documented ethnopharmacological properties have been associated with Swietenia macrophylla (Meliaceae), with its seed extract reported to display anti-hypoglycemic activities in diabetic rats. In the present study, three compounds isolated from the seeds of S. macrophylla were tested on a modified ELISA binding assay and showed to possess PPARγ ligand activity. They were corresponded to PPARγ-mediated cellular response, stimulated adipocyte differentiation but produced lower amount of fat droplets compared to a conventional anti-diabetic agent, rosiglitazone. The up-regulation of adipocytes was followed by increased adipocyte-related gene expressions such as adiponectin, adipsin, and PPARγ. The S. macrophylla compounds also promoted cellular glucose uptake via the translocation of GLUT4 glucose transporter.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications